ERBB receptors and cancer: the complexity of targeted inhibitors - PubMed

Affiliations

• PMID: 15864276
• DOI: 10.1038/nrc1609

Review

ERBB receptors and cancer: the complexity of targeted inhibitors

Nancy E Hynes et al. Nat Rev Cancer. 2005 May.

Erratum in

• Nat Rev Cancer. 2005 Jul;5(7):580

Abstract

ERBB receptor tyrosine kinases have important roles in human cancer. In particular, the expression or activation of epidermal growth factor receptor and ERBB2 are altered in many epithelial tumours, and clinical studies indicate that they have important roles in tumour aetiology and progression. Accordingly, these receptors have been intensely studied to understand their importance in cancer biology and as therapeutic targets, and many ERBB inhibitors are now used in the clinic. We will discuss the significance of these receptors as clinical targets, in particular the molecular mechanisms underlying response.

Similar articles

• ErbB receptors and signaling pathways in cancer.

  Hynes NE, MacDonald G. Hynes NE, et al. Curr Opin Cell Biol. 2009 Apr;21(2):177-84. doi: 10.1016/j.ceb.2008.12.010. Epub 2009 Feb 7. Curr Opin Cell Biol. 2009. PMID: 19208461 Review.

• ErbB receptor tyrosine kinase inhibitors as therapeutic agents.

  Anderson NG, Ahmad T. Anderson NG, et al. Front Biosci. 2002 Sep 1;7:d1926-40. doi: 10.2741/A889. Front Biosci. 2002. PMID: 12161338 Review.

• [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].

  Dalmases A, Rojo F, Rovira A, Albanell J. Dalmases A, et al. Med Clin (Barc). 2013 Aug 17;141(4):176-80. doi: 10.1016/j.medcli.2013.04.008. Epub 2013 Jun 27. Med Clin (Barc). 2013. PMID: 23809407 Review. Spanish. No abstract available.

• Targeting the ERBB family in cancer: couples therapy.

  Tebbutt N, Pedersen MW, Johns TG. Tebbutt N, et al. Nat Rev Cancer. 2013 Sep;13(9):663-73. doi: 10.1038/nrc3559. Epub 2013 Aug 16. Nat Rev Cancer. 2013. PMID: 23949426 Review.

• Mechanisms of resistance to ErbB-targeted cancer therapeutics.

  Wang Q, Greene MI. Wang Q, et al. J Clin Invest. 2008 Jul;118(7):2389-92. doi: 10.1172/JCI36260. J Clin Invest. 2008. PMID: 18568082 Free PMC article.

Cited by

• Erlotinib resistance in lung cancer: current progress and future perspectives.

  Tang J, Salama R, Gadgeel SM, Sarkar FH, Ahmad A. Tang J, et al. Front Pharmacol. 2013 Feb 13;4:15. doi: 10.3389/fphar.2013.00015. eCollection 2013. Front Pharmacol. 2013. PMID: 23407898 Free PMC article.

• Soluble E-cadherin: a critical oncogene modulating receptor tyrosine kinases, MAPK and PI3K/Akt/mTOR signaling.

  Brouxhon SM, Kyrkanides S, Teng X, Athar M, Ghazizadeh S, Simon M, O'Banion MK, Ma L. Brouxhon SM, et al. Oncogene. 2014 Jan 9;33(2):225-35. doi: 10.1038/onc.2012.563. Epub 2013 Jan 14. Oncogene. 2014. PMID: 23318419 Free PMC article.

• Second-line panitumumab as a triweekly dose for patients with wild-type KRAS exon 2 metastatic colorectal cancer: a single-institution experience.

  Daoud MA, Aboelnaga EM, Mohamed WM. Daoud MA, et al. Cancer Biol Med. 2016 Mar;13(1):136-41. doi: 10.28092/j.issn.2095-3941.2015.0009. Cancer Biol Med. 2016. PMID: 27144068 Free PMC article.

• The potential role of aerobic exercise to modulate cardiotoxicity of molecularly targeted cancer therapeutics.

  Scott JM, Lakoski S, Mackey JR, Douglas PS, Haykowsky MJ, Jones LW. Scott JM, et al. Oncologist. 2013;18(2):221-31. doi: 10.1634/theoncologist.2012-0226. Epub 2013 Jan 18. Oncologist. 2013. PMID: 23335619 Free PMC article. Review.

• Spatial regulation of receptor tyrosine kinases in development and cancer.

  Casaletto JB, McClatchey AI. Casaletto JB, et al. Nat Rev Cancer. 2012 May 24;12(6):387-400. doi: 10.1038/nrc3277. Nat Rev Cancer. 2012. PMID: 22622641 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal